Welcome to my homepage! I am a Physical Chemist by training, I teach drug formulation science into the Pharmacy and Pharmaeutical Science Programs, nanotechnology in the Bachelor of Science Program. I am the author of more than 40 refereed international journal articles, text book chapters and conference papers, as well as more than 30 major reports to industry. I have supervised 8 PhD students and more than 20 honours and research project students.
I am actively involved in the Prestidge Research Group, which is focussed on Nanomedicine and Biopharmaceutical Engineering - I am interested in developing novel therapeutic delivery strategies for both small molecule and protein pharmaceuticals. I have also consulted for... Read more
About me
Welcome to my homepage! I am a Physical Chemist by training, I teach drug formulation science into the Pharmacy and Pharmaeutical Science Programs, nanotechnology in the Bachelor of Science Program. I am the author of more than 40 refereed international journal articles, text book chapters and conference papers, as well as more than 30 major reports to industry. I have supervised 8 PhD students and more than 20 honours and research project students.
I am actively involved in the Prestidge Research Group, which is focussed on Nanomedicine and Biopharmaceutical Engineering - I am interested in developing novel therapeutic delivery strategies for both small molecule and protein pharmaceuticals. I have also consulted for numerous Pharmaceutical companies both within Australia and internationally.
About me
Royal Australian Chemistry Institute, Controlled Release Society (Australia)
About me
Doctor of Philosophy University of South Australia
Graduate Diploma of Education The University of Adelaide
Bachelor of Applied Science University of South Australia
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2016 |
Open access
14
12
|
| 2015 |
31
26
1
|
| 2014 |
1
|
| 2013 |
Open access
|
| 2012 |
45
42
|
| Year | Output |
|---|---|
| 2024 |
Open access
|
| 2023 |
Open access
|
| 2023 |
Open access
3
3
64
|
| 2023 |
Open access
3
|
| 2023 |
Open access
4
|
| 2023 |
11
12
|
| 2022 |
Open access
8
8
121
|
| 2022 |
35
35
72
|
| 2022 |
Open access
3
3
1
|
| 2021 |
Open access
9
9
10
|
| 2020 |
Open access
24
23
9
|
| 2020 |
24
21
6
|
| 2019 |
Open access
5
4
3
|
| 2016 |
Open access
14
12
|
| 2016 |
34
33
|
| 2016 |
3
|
| 2015 |
13
14
|
| 2015 |
31
26
1
|
| 2014 |
Open access
14
13
|
| 2013 |
31
18
|
| 2013 |
Open access
|
| 2012 |
45
42
|
| 2011 |
47
47
|
| 2011 |
41
38
|
| 2011 |
29
26
|
| 2010 |
4
|
| 2010 |
40
37
|
| 2010 |
132
117
|
| 2010 |
127
111
|
| 2010 |
32
32
|
| 2010 |
46
45
|
| 2010 |
Open access
26
21
|
| 2009 |
32
28
|
| 2008 |
5
5
|
| 2008 |
5
6
|
| 2008 |
46
44
|
| 2008 |
34
29
|
| 2008 |
42
39
|
| 2008 |
55
52
|
| 2008 |
37
36
|
Research
External engagement & recognition
| Organisation | Country |
|---|---|
| Charles Darwin University | AUSTRALIA |
| Fermiscan Holdings Ltd. | AUSTRALIA |
| Monash University | AUSTRALIA |
| pSiMedica Ltd | UNITED KINGDOM |
| Umeå University | SWEDEN |
| University of Adelaide | AUSTRALIA |
| University of New South Wales | AUSTRALIA |
| University of North Bengal | INDIA |
| University of Otago | NEW ZEALAND |
| University of Parma | ITALY |
| University of South Australia | AUSTRALIA |
| University of Technology Sydney | AUSTRALIA |
| Uppsala University | SWEDEN |
External engagement & recognition
| Engagement/recognition | Year |
|---|---|
MemberRoyal Australian Chemistry Institute |
2017 |
MemberInternational Union of Pure and Applied Chemistry |
2017 |
MemberAustralasian Pharmaceutical Science Association (APSA) |
2017 |
MemberControlled Release Society (Australia) |
2017 |
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
| Thesis title | Student status |
|---|---|
| Conquering antimicrobial resistant Gram-negative bacteria to address unmet clinical needs | Current |
| Developing advanced oral delivery systems for antiviral drugs | Current |
| Beyond the gastrointestinal cell layer: replication of the complex oral absorption barrier through enhanced in vitro models for nanoparticulate oral protein delivery | Completed |
| Dendrimers interactions with lipid bilayers: mechanistic and kinetic studies | Completed |
| Lipid liquid crystalline nanoparticles: a delivery system for antimicrobial photodynamic therapy | Completed |
| Liposome-micelle hybrid systems for oral delivery of poorly water-soluble cardiovascular drug lovastatin and anticancer drugs paclitaxel and 5-fluorouracil | Completed |
| Multi-compartmental emulsion systems for the oral delivery of subunit vaccines | Completed |
| Nanoparticle coated liposomes for encapsulation and delivery of proteins | Completed |
| Novel glyceryl monooleate (GMO) cubosomes stabilized using silica nanoparticles for the oral delivery of poorly water soluble drugs | Completed |
| Optimising the interfacial properties of porous silicon for effective control of molecular and biomolecular interactions | Completed |
| Porous silicon as a delivery system for poorly soluble drugs | Completed |
